🧬Breaking: Triumvira Immunologics sharing TACTIC-3 trial data at #SITC2024! Dr. Ecaterina Dumbrava of MD Anderson Cancer Center presents TAC101-CLDN18.2 solid tumor therapy results Nov 8. #CellTherapy #CancerResearch #Oncology

Excited to share! Our President & COO Robert Williamson sat down with @Rahulc on the Biotech2050 Podcast to talk career journey, leadership at Triumvira Immunologics, and his driving passion for developing life-changing therapeutics 🎙️ Check it out: bit.ly/3YRJ6Z9 #CellTherapy

Honored that our late-breaking abstract on TACTIC-3 was selected for oral presentation at #SITC2024! Thank you Society for Immunotherapy of Cancer for this opportunity and Dr. Ecaterina Dumbrava of MD Anderson Cancer Center for presenting our promising data! Check it out: prn.to/4fKedLB #SITC2024

More exciting news from #SITC2024! MD Anderson Cancer Center featured our oral presentation on TAC01-CLDN18.2's safety & promising clinical activity in Claudin 18.2+ solid tumors in their SITC Special Edition. Read more: bit.ly/48VDU9Z #Immunotherapy #CellTherapy #CancerResearch

What an incredible turnout at #SITC2024! Thank you to everyone who attended our presentation, to Dr. Dumbrava for delivering it brilliantly, and to Society for Immunotherapy of Cancer for a fantastic event! #CellTherapy #CancerResearch

💜 November is #StomachCancer Awareness Month Triumvira Immunologics is advancing breakthrough cell therapies targeting Claudin 18.2+ tumors to help gastric cancer patients. Together, we're bringing new hope to patients and their families. #GastricCancer #CellTherapy

Excited to announce! 📢 Jeffrey Erickson will present on Next-Gen Cell Therapies Targeting Claudin at #ClaudinSummit2024. Learn more here: bit.ly/49ksLjc #Immunotherapy #CellTherapy #CancerResearch

Check out this infographic illustrating the latest gastric cancer statistics from American Cancer Society Awareness, early detection, and prompt treatment are critical. #CancerAwareness #CellTherapy

Happy holidays from Triumvira! Thank you for being part of our journey in revolutionizing cell therapies. #CellTherapy #CancerResearch

🧬 As we look ahead to 2025, we're grateful for a year of significant progress in our cell therapy innovation. Thanks to our team, partners & trial patients who inspire us every day. #CellTherapy #CancerResearch #Innovation

Triumvira Immunologics is advancing cancer cell therapy on two fronts: personalized treatments using patients’ own immune cells and ‘off-the-shelf' therapies. #Immunotherapy #CellTherapy #CancerResearch

Excited to share that clinical data from our TACTIC-3 trial will be presented at the 2025 #ASCO GI Symposium by Dr. Ecaterina Dumbrava of MD Anderson Cancer Center See the following link for additional details: bit.ly/4hnCNTn #Immunotherapy #CellTherapy #CancerResearch

📢 Clinical updates from TACTIC-3: Our TAC-T cell candidate therapy shows promising results in Claudin 18.2+ solid tumors Full details: prn.to/3WwRHPp #Immunotherapy #CellTherapy #CancerResearch

On World Cancer Day, we take a moment to recognize the incredible resilience that defines the cancer community. #Immunotherapy #CellTherapy #CancerResearch

Clinical updates from Triumvira’s TACTIC-3 trial were included in a roundup article by BioWorld. Check out the article here: bit.ly/4gTgPaa #CellTherapy #Immunotherapy

Triumvira Immunologics will be presenting updated clinical data at the Society for Immunotherapy of Cancer Spring Conference. Learn more here: prn.to/3DLV7Yb #Immunotherapy #CellTherapy #CancerResearch

Triumvira Immunologics Chief Technology Officer, Donna Rill, delivered a thought-provoking presentation at the 2025 Advanced Therapies Week conference. Check out the full presentation here: bit.ly/4ikxhRy #Immunotherapy #CellTherapy #CancerResearch

We’re honored to be featured in CGTLive®'s recent article highlighting the advancements in cell therapies over the past year. Check out the full article here: bit.ly/4jdUINI #Immunotherapy #CellTherapy #CancerResearch

Our Acting President & CEO Robert Williamson had an intriguing chat on BioWorld Insider Podcast with Lynn Yoffee, offering perspective on recent tariffs and NIH grant cuts impacting clinical research. Listen here: bit.ly/4lLIJZu #Immunotherapy #CellTherapy

Last year, our Vice President of Business Development, Jeffrey Erickson, shared valuable insights on non-gene-edited therapeutics with Pharmaceutical Executive. Check out the full article here: bit.ly/3PMtIIH #Immunotherapy #CellTherapy #CancerResearch